Indeed, the U.S. Food and Drug Administration has recently approved pembrolizumab in combination with chemotherapy for esophageal and GEJ malignancy regardless of PD-L1 status based on the results from KEYNOTE-590 (28), and the National Comprehensive Cancer Network (NCCN) has altered their recommendations for first-line therapy for gastric cancer to include nivolumab for CPS of 5 or greater (29). Here, CD274 is linked to gastric cancer.